Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 50 50 PEN versus HUMALOG TEMPO PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 50 50 PEN versus HUMALOG TEMPO PEN.
HUMALOG MIX 50/50 PEN vs HUMALOG TEMPO PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on liver, muscle, and adipose tissue, promoting glucose uptake and storage, and inhibiting hepatic glucose production.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially in skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase and downstream signaling pathways.
Subcutaneous injection, 0.5 to 1 unit/kg/day divided into two doses (before breakfast and before dinner), individualized based on blood glucose levels.
Subcutaneously, 0.2-0.5 units/kg within 15 minutes before or after a meal. Total daily dose is 0.5-1.0 units/kg.
None Documented
None Documented
Terminal half-life: 0.5-1.0 hour (insulin lispro); clinical context: short duration due to rapid clearance.
1.0 hour (terminal elimination half-life); reflects rapid clearance of insulin lispro from circulation.
Renal: 75-80% as metabolites; hepatic: 20-25% via biliary elimination.
Renal: 100% of absorbed dose is eliminated via degradation, primarily in the liver and kidneys; no significant biliary/fecal excretion.
Category C
Category C
Insulin Analog
Insulin Analog